Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren’s disease. This fusion protein could compete against a Novartis antibody under an FDA review that could make it the first Sjögren’s therapy.
The post Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds appeared first on MedCity News.
